Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|April 24, 2020
Safety and Efficacy of Revefenacin and Formoterol in Sequence and Combination via a Standard Jet Nebulizer in Patients with Chronic Obstructive Pulmonary Disease: A Phase 3b, Randomized, 42-Day StudyThomas M Siler, Edmund J Moran, Chris N Barnes, et al.
Respiratory Research|November 4, 2017
A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary diseaseKrishna K Pudi, Chris N Barnes, Edmund J Moran, et al.
International Journal of Chronic Obstructive Pulmonary Disease|October 22, 2019
Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic functionMarie T Borin, Arthur Lo, Chris N Barnes, et al.
Therapeutic Advances in Respiratory Disease|February 29, 2020
Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trialsSanjay Sethi, James F Donohue, Gary T Ferguson, et al.
Chest|April 29, 2020
Peak Inspiratory Flows: Defining Repeatability Limits and a Predictive Equation for Different InhalersChris N Barnes, Donald A Mahler, Jill A Ohar, et al.
Clinical Pharmacology in Drug Development|August 31, 2019
Revefenacin, a Long-Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo- and Positive-Controlled Thorough QT StudyMarie T Borin, Chris N Barnes, Borje Darpo, et al.
Infectious Diseases and Therapy|August 3, 2019
Telavancin in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) Caused by Staphylococcus aureus: Post Hoc Analysis of 2 Randomized, Controlled TrialsMichael S Niederman, Patrick C Lee, Steven L Barriere, et al.
BMC Pulmonary Medicine|May 13, 2020
Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysisJames F Donohue, Edward Kerwin, Chris N Barnes, et al.
JPEN. Journal of Parenteral and Enteral Nutrition|January 29, 2020
Blinded, Double-Dummy, Parallel-Group, Phase 2a Randomized Clinical Trial to Evaluate the Efficacy and Safety of a Highly Selective 5-Hydroxytryptamine Type 4 Receptor Agonist in Critically Ill Patients With Enteral Feeding IntoleranceMarianne J Chapman, Karen L Jones, Cristina Almansa, et al.
Pulmonary Pharmacology & Therapeutics|June 2, 2019
Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trialsJames F Donohue, Gregory Feldman, Sanjay Sethi, et al.
Pageof 3